HAART Administration and Outpatient Care

Treatment Setting Recommendations

The primary location for HAART administration is outpatient clinical settings where regular monitoring and adherence support can be provided, according to the American College of Physicians, as published in the Annals of Internal Medicine 1, 2
Intensive follow-up should occur in these outpatient settings to assess adherence to treatment and continue patient counseling for prevention of transmission, as recommended by the American College of Physicians, with a strength of evidence based on clinical trials 1
Discussion of sexual and needle-sharing practices should be integrated as a routine part of clinical care during outpatient visits, as suggested by the Centers for Disease Control and Prevention, with a moderate strength of evidence based on observational studies 3, 4

Patients with chronic, stable HIV should be seen regularly in healthcare settings where risk behavior assessment and STD screening occur periodically, such as annually, as recommended by the Centers for Disease Control and Prevention, with a high strength of evidence based on systematic reviews 3, 4
CD4 count monitoring should occur every 6 months until consistently above 250 cells/μL for at least 1 year with concurrent viral suppression, as suggested by the National Institutes of Health, with a moderate strength of evidence based on clinical trials 5
HIV RNA monitoring should occur every 3 months until viral suppression below 50 copies/mL is achieved and maintained for at least 1 year, as recommended by the National Institutes of Health, with a high strength of evidence based on systematic reviews 5

HAART initiation requires intensive patient education and support regarding the critical need for adherence, with specific goals of therapy established and mutually agreed upon, as recommended by the American College of Physicians, with a high strength of evidence based on clinical trials 1, 2
Follow-up assessment should occur within 4-6 weeks of ART initiation to measure HIV RNA level, assess adherence, and evaluate for adverse effects, as suggested by the National Institutes of Health, with a moderate strength of evidence based on observational studies 5

Patients should not be switched between multiple care sites unnecessarily, as this disrupts the intensive follow-up needed to assess adherence and provide ongoing counseling, as recommended by the American College of Physicians, with a high strength of evidence based on clinical trials 1, 2
Lack of reliable access to primary medical care or medication is a predictor of inadequate adherence, so HAART should be provided at locations where patients can reliably access both clinical services and pharmacy services, as suggested by the American College of Physicians, with a moderate strength of evidence based on observational studies 1, 2